These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 15494404)

  • 1. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.
    Gardian G; Browne SE; Choi DK; Klivenyi P; Gregorio J; Kubilus JK; Ryu H; Langley B; Ratan RR; Ferrante RJ; Beal MF
    J Biol Chem; 2005 Jan; 280(1):556-63. PubMed ID: 15494404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems.
    Jia H; Kast RJ; Steffan JS; Thomas EA
    Hum Mol Genet; 2012 Dec; 21(24):5280-93. PubMed ID: 22965876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
    Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
    Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of nucleosome dynamics in Huntington's disease.
    Stack EC; Del Signore SJ; Luthi-Carter R; Soh BY; Goldstein DR; Matson S; Goodrich S; Markey AL; Cormier K; Hagerty SW; Smith K; Ryu H; Ferrante RJ
    Hum Mol Genet; 2007 May; 16(10):1164-75. PubMed ID: 17403718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
    Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
    J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
    Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
    J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards a transgenic model of Huntington's disease in a non-human primate.
    Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
    Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice.
    Bradford J; Shin JY; Roberts M; Wang CE; Sheng G; Li S; Li XJ
    J Biol Chem; 2010 Apr; 285(14):10653-61. PubMed ID: 20145253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of interleukin-1 type 1 receptor enhances the accumulation of mutant huntingtin in the striatum and exacerbates the neurological phenotypes of Huntington's disease mice.
    Wang CE; Li S; Li XJ
    Mol Brain; 2010 Nov; 3():33. PubMed ID: 21044321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease.
    Vamos E; Voros K; Zadori D; Vecsei L; Klivenyi P
    J Neural Transm (Vienna); 2009 Sep; 116(9):1079-86. PubMed ID: 19551467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.
    Moreno CL; Ehrlich ME; Mobbs CV
    Neurobiol Dis; 2016 Jan; 85():25-34. PubMed ID: 26485309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice.
    Jia H; Wang Y; Morris CD; Jacques V; Gottesfeld JM; Rusche JR; Thomas EA
    PLoS One; 2016; 11(3):e0152498. PubMed ID: 27031333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
    Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
    Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice.
    Wang J; Wang CE; Orr A; Tydlacka S; Li SH; Li XJ
    J Cell Biol; 2008 Mar; 180(6):1177-89. PubMed ID: 18362179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
    Sadri-Vakili G; Cha JH
    Curr Alzheimer Res; 2006 Sep; 3(4):403-8. PubMed ID: 17017871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial depletion of CREB-binding protein reduces life expectancy in a mouse model of Huntington disease.
    Klevytska AM; Tebbenkamp AT; Savonenko AV; Borchelt DR
    J Neuropathol Exp Neurol; 2010 Apr; 69(4):396-404. PubMed ID: 20448484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.